Gilead’s HIV Triple Combo Gets Sped-up FDA Review, Decision Date Locked Down


Feb. 12, 2018, is the day the U.S. Food and Drug Administration is expected to review Gilead Sciences' HIV treatment that some analysts suggest could become a blockbuster.
Source link